Brian co-founded Link in 2022 with Robbie Majzner, M.D., and Crystal Mackall, M.D., and has served on the Board of Directors. He previously co-founded and was the CEO of Stemcentrx, a next-generation ADC company that pursued novel targets with limited or no normal tissue expression, including DLL3 and SEZ6, and built the industry’s first end-to-end ADC GMP manufacturing facility. Abbvie acquired Stemcentrx in 2016 for $6.2 billion, which at the time was the largest private acquisition of all time in biotechnology. Prior to founding Stemcentrx, Brian was a Founding Partner at Qatalyst Partners and Vice President at Goldman Sachs where he helped companies raise private venture capital, execute IPOs and other financings, advised on mergers and acquisitions, and gained valuable experience working with CEOs at various stages of development. Brian has held other biotechnology CEO roles, including of recently acquired Convergent Genomics, and Everest Detection, and served on the Boards of Directors and provided initial capital to multiple biotech companies including Enliven Therapeutics (Nasdaq: ELVN). Brian is a graduate of Virginia Tech.